Skip to main content
Caplight Logo









EraCal Therapeutics

EraCal Therapeutics

Private
SchlierenHealthcare & Life Scienceshttps://www.eracal.ch/

Last Round

Seed

Oct 16, 2019

Total Funding Raised

$1.14M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

EraCal Therapeutics is a biotechnology company that develops drugs to treat metabolic syndrome and obesity using its in-vivo screening platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Application

Keywords

drug discoveryzebrafish screeningobesity treatmentappetite suppressorphenotypic screeningweight loss drugssmall molecule drugsbiopharma licensingmetabolic diseasepreclinical drug developmentnovel drug targetszebrafish modelin-vivo screening

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

EraCal Therapeutics Comparables

Compare EraCal Therapeutics with similar companies based on industry and business-model similarity.

EraCal Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Resalis Therapeutics
76%
Kallyope
74%
Metaphore Biotechnologies
67%

EraCal Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedOct 16, 2019
GrantFeb 1, 2019

EraCal Therapeutics Investors

Notable investors and investment history

EraCal Therapeutics investors
InvestorRounds
University of ZurichSeed
RedalpineSeed
Venture KickGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors grew 132% MoM.

  • Jul 3, 2025

    Monthly visitors increased 151% MoM, reaching 1.1K.

EraCal Therapeutics Filings

Explore SEC and related filing metadata, where available.

EraCal Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about EraCal Therapeutics's valuation, stock price, and market status.

Is EraCal Therapeutics a public or private company?

EraCal Therapeutics is a private company.

What is the current stock price of EraCal Therapeutics?

EraCal Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is EraCal Therapeutics worth (valuation)?

Valuation information for EraCal Therapeutics is not publicly available.

Can I buy EraCal Therapeutics stock?

EraCal Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was EraCal Therapeutics's last funding round?

EraCal Therapeutics's most recent funding round was Seed on October 16, 2019.

Who are the main investors in EraCal Therapeutics?

Key investors in EraCal Therapeutics include Redalpine.

Will EraCal Therapeutics IPO soon?

No public IPO plans have been announced for EraCal Therapeutics.

How can I track EraCal Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor EraCal Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSchlieren
Employee Range4
Year Founded2018
Last FundingOct 16, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?